Skip to content

Study · Animal study (in vivo) · rat · 2000

5 results

Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat.

Thomas GB, Bennett PA, Carmignac DF, Robinson IC

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Feb 2000Cited by 21 (Europe PMC)

PMID10753592 (opens in a new tab)DOI10.1054/ghir.1999.0138 (opens in a new tab)PepBankPUB-10753592
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, GHRP‑6 did not significantly change weight gain versus excipient controls.

    In plain wordsIn rats with intact adrenal glands, GHRP‑6 did not significantly change weight gain versus excipient controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeWeight gain in intact rats
    Study

    ratn: not reported in source

    female intact or adrenalectomized rats
    Comparator
    Excipient-treated controls
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    100 mg/day · subcutaneous · 14 daysAs given in this study (rat).

    Measurements

    Weight gain
    9 g
    controls
    Weight gain
    11.8 g
    GHRP-6

    Source sentences

    Summary
    Infusion of GHRP-6 did not significantly affect body weight gain compared with excipient-treated controls in either intact rats (controls, 9.0 +/- 1.6 vs GHRP-6, 11.8 +/- 0.9 g) or Adx rats (4.4 +/- 1.5 vs 7.9 +/- 2.7 g).
    1 context sentence
    Summary · context
    We have now examined the effects of continuous GHRP-6 infusion (100 mg/day, s.c. for 14 days) in normal 150-day-old female rats, and in adrenalectomized (Adx) rats with or without dexamethasone (Dex) replacement.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adrenalectomized rats, GHRP‑6 did not significantly change weight gain versus excipient controls.

    In plain wordsIn adrenalectomized rats, GHRP‑6 did not significantly change weight gain versus excipient controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeWeight gain in adrenalectomized rats
    Study

    ratn: not reported in source

    female intact or adrenalectomized rats
    Comparator
    Excipient-treated controls
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    100 mg/day · subcutaneous · 14 daysAs given in this study (rat).

    Measurements

    Weight gain
    4.4 g
    controls
    Weight gain
    7.9 g
    GHRP-6

    Source sentences

    Summary
    Infusion of GHRP-6 did not significantly affect body weight gain compared with excipient-treated controls in either intact rats (controls, 9.0 +/- 1.6 vs GHRP-6, 11.8 +/- 0.9 g) or Adx rats (4.4 +/- 1.5 vs 7.9 +/- 2.7 g).
    1 context sentence
    Summary · context
    We have now examined the effects of continuous GHRP-6 infusion (100 mg/day, s.c. for 14 days) in normal 150-day-old female rats, and in adrenalectomized (Adx) rats with or without dexamethasone (Dex) replacement.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated adrenalectomized rats, GHRP‑6 increased weight gain versus excipient controls.

    In plain wordsIn adrenalectomized rats receiving dexamethasone, GHRP‑6 increased weight gain versus excipient controls.

    Peptide
    GHRP-6
    Outcome
    IncreaseWeight gain with dexamethasone replacement
    Study

    ratn: not reported in source

    female intact or adrenalectomized rats
    Comparator
    Excipient-treated controls
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    100 mg/day · subcutaneous · 14 daysAs given in this study (rat).

    Measurements

    Weight gain
    3.5 g
    controls
    Weight gain
    15.4 g
    GHRP-6

    Source sentences

    Summary
    However, GHRP-6 significantly increased weight gain in Adx rats treated with Dex (controls, 3.5 +/- 1.4 vs GHRP-6, 15.4 +/- 1.6 g;P<0.01).
    1 context sentence
    Summary · context
    We have now examined the effects of continuous GHRP-6 infusion (100 mg/day, s.c. for 14 days) in normal 150-day-old female rats, and in adrenalectomized (Adx) rats with or without dexamethasone (Dex) replacement.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GHRP‑6 did not affect plasma triglycerides versus excipient-treated controls.

    In plain wordsIn rats, GHRP‑6 did not change plasma triglycerides versus excipient-treated controls.

    Peptide
    GHRP-6
    Outcome
    No significant changePlasma triglycerides
    Study

    ratn: not reported in source

    female intact or adrenalectomized rats
    Comparator
    Excipient-treated controls
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    100 mg/day · subcutaneous · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Adrenalectomy decreased plasma triglycerides (P<0.01), and Dex treatment increased plasma cholesterol (P<0.001), GHRP-6 treatment did not affect these plasma lipids.
    1 context sentence
    Summary · context
    We have now examined the effects of continuous GHRP-6 infusion (100 mg/day, s.c. for 14 days) in normal 150-day-old female rats, and in adrenalectomized (Adx) rats with or without dexamethasone (Dex) replacement.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GHRP‑6 did not affect plasma cholesterol versus excipient-treated controls.

    In plain wordsIn rats, GHRP‑6 did not change plasma cholesterol versus excipient-treated controls.

    Peptide
    GHRP-6
    Outcome
    No significant changePlasma cholesterol
    Study

    ratn: not reported in source

    female intact or adrenalectomized rats
    Comparator
    Excipient-treated controls
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    100 mg/day · subcutaneous · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    Adrenalectomy decreased plasma triglycerides (P<0.01), and Dex treatment increased plasma cholesterol (P<0.001), GHRP-6 treatment did not affect these plasma lipids.
    1 context sentence
    Summary · context
    We have now examined the effects of continuous GHRP-6 infusion (100 mg/day, s.c. for 14 days) in normal 150-day-old female rats, and in adrenalectomized (Adx) rats with or without dexamethasone (Dex) replacement.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.